When biologics to treat inflammatory bowel disease (IBD) were first released over two decades ago, they greatly improved quality of life for many patients. But these first-generation therapies have their shortcomings. Fewer than half of patients treated with these inflammation-blocking drugs will be in remission after one year of treatment. These treatments can also suppress the immune system, making patients vulnerable to infection.
